<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>focus</title>

    <!-- bootstrap css -->
    <link rel="stylesheet" href="asset/css/bootstrap.min.css" />
    <!-- owl-carousel  -->
    <link rel="stylesheet" href="asset/css/owl.carousel.min.css" />
    <!-- main CSS -->
    <link rel="stylesheet" href="asset/css/main.css" />
</head>

<body>
    <!-- ========================= -->
    <!-- header section  -->
    <!-- ========================= -->
    <div class="header-top-cnt blue">
        <p>THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY</p>
    </div>
    <header class="header">
        <nav class="navbar navbar-expand-lg navbar-light p-0">
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav align-items-center me-auto">
                    <li class="nav-item">
                        <a href="home.html" class="header-link">
                            <img src="asset/image/Home-icon.png" alt="" />
                            HOME</a>
                    </li>
                    <li class="nav-item active">
                        <a href="patient_experience.html" class="header-link">
                            <img src="asset/image/Patient-icon.png" alt="" />
                            patient experience</a>
                    </li>
                    <li class="nav-item">
                        <a href="about_brintellix.html" class="header-link">
                            <img src="asset/image/AB_ico.png" alt="" />
                            ABOUT BRINTELLIX</a>
                    </li>
                    <li >
                        <a href="#ref" class="header-link ref">
                            <img src="asset/image/AE_icon.png" alt="" />
                            report an adverse Event</a>
                    </li>
                    <li class="nav-item">
                        <a href="asset/pdf/Brintellix Prescribing Information (April 2022) for digital use v5.pdf" target="_blank" class="header-link">
                            <img src="asset/image/PI_icon.png" alt="" />
                            prescribing information</a>
                    </li>
                </ul>
            </div>

            <a class="navbar-brand logo" href="home.html"><img src="asset/image/logo.png" alt="" /></a>
            <button id="nav-burger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </button>
        </nav>
        <hr class="divider" />
    </header>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel-sec ">
        <div class="li li-four" data-parallax="scroll" data-image-src="asset/image/feel-sec-bg4.png" data-z-index="1">
            <div class="nav-btn">
                <a href="forward.html" class="arrow-btn"><img src="asset/image/left-arrow.png" alt=""></a>
                <a href="maintain.html" class="arrow-btn arrow-btn-right"><img src="asset/image/right-arrow.png"
                        alt=""></a>
            </div>
            <div class="container">
                <div class="banner-wraper">
                    <p class="major">
                        Brintellix (vortioxetine) is indicated for the treatment of major
                        depressive episodes in adults.¹<br />
                        Prescribing information can be accessed via the tab at the top of
                        this page.
                    </p>
                    <div class="feel-sec-cnt ">
                        <h2>I want to FOCUS</h2>
                        <figure class="feel-image">
                            <img src="asset/image/feel-sec-img4.png" alt="" />
                        </figure>
                        <h3>
                            Could Brintellix help adult patients like Peter with MDD who are struggling with impaired
                            cognition?
                        </h3>
                    </div>
                </div>
            </div>
            <ul class="dots-body">
                <li></li>
                <li></li>
                <li></li>
                <li class="active"></li>
                <li></li>
            </ul>
            <span class="used">Fictional patients used for illustrative purposes.</span>
        </div>
    </section>
    <!-- ========================= -->
    <!-- feelings section  -->
    <!-- ========================= -->
    <section class="feelings cmn-banner">
        <figure class="feelings-bg">
            <img class="feelings-bg1" src="asset/image/feelings-bg2.png" alt="" />
            <img class="display-none" src="asset/image/orange-sm-bg.png" alt="">
        </figure>
        <div class="container">
            <div class="row flex-md-column-reverse flex-sm-column-reverse flex-column-reverse flex-lg-row">
                <div class="col-lg-6">
                    <div class="feelings-cnt-left">
                        <div class="feelings-top-cnt">
                            <h4>
                                As a care-home worker and amateur theatre actor, it’s
                                important for Peter to be able to focus on both his work and
                                his hobby.
                            </h4>
                            <p>
                                But recently, he’s been experiencing brain fog and has
                                struggled to remember things. Last week, he forgot about a
                                deadline for a job application, and he missed the deadline.
                            </p>
                        </div>
                        <div class="defined-cnt">
                            <h4>MDD and cognitive function:</h4>
                            <p>
                                In addition to mood and physical symptoms, most patients with
                                MDD present with cognitive symptoms, such as trouble
                                concentrating, indecisiveness and poor attention, which can
                                affect their daily functioning <sup>2,3</sup>
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="feelings-cnt-right">
                        <figure class="round-img">
                            <img src="asset/image/round-img4.png" alt="" />
                        </figure>
                        <h2>
                            Brintellix may help people like Peter improve their cognitive
                            symptoms, helping them be more productive at work (vs.
                            baseline)⁴
                        </h2>
                        <span class="depressive"><strong>MDD,</strong> major depressive disorder.  </span>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing section  -->
    <!-- ========================= -->
    <section class="design desing-white-bg padding-btm">
        <div class="container2">
            <div class="row desing-row  ">
                <div class="design-left">
                    <h4>
                        Patients receiving Brintellix experience improvements from
                        baseline in cognition⁴
                    </h4>
                    <p>
                        <strong>The AtWoRC study was an open-label, flexible dose study which
                            assessed whether improvements in cognitive symptoms in
                            Brintellix-treated patients correlated with increased work
                            productivity in a real-life setting vs. baseline:⁴  </strong>
                    </p>
                    <ul class="both">
                        <li>
                            <span class="week"><strong>Statistically significant improvements in cognition were
                                    observed at Week 52</strong> vs. baseline (as measured on DSST; p< 0.001, paired t
                                    test)</span>
                        </li>
                        <li>
                            <span class="week">Patient-reported improvements in cognitive symptoms were
                                significantly correlated with work productivity</span>
                        </li>
                        <li>
                            <span class="week">
                                Primary study endpoint was the partial correlation between
                                changes in PDQ-D-20 and WLQ productivity loss scores at Week
                                12 - a <strong>significant association</strong> was seen <strong>for both ‘first
                                    treatment’ and ‘switch’ patients (r=0.606; p< 0.001)*</strong></span>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal6">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="font-size-20-wh">
                            Cognition: mean DSST score over 52 weeks (n=199)†
                        </span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img11.png" alt="" />
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Chokka P et al. 2019.4</span>
                            <span class="adapted pb-2">†Changes in DSST over 52 weeks of follow-up are shown; error bars
                                indicate 95% confidence intervals.</span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    *Correlation was assessed by the partial correlation coefficient adjusted for age, sex, baseline
                    PDQ-D-20, baseline WLQ productivity loss, disease duration, and disease severity.
                </p>
                <p>AtWoRC, Assessment in Work productivity and the Relationship with Cognitive symptoms; DSST, Digit
                    Symbol Substitution Test; FAS, Full Analysis Set; PDQ-D-20, 20-item Perceived Deficits Questionnaire
                    – Depression; WLQ, Work Limitations Questionnaire.</p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing-2 section  -->
    <!-- ========================= -->
    <section class="design desing-white-bg pt-0">
        <div class="container2">
            <div class="row desing-row   flex-lg-row-reverse">
                <div class="design-left">
                    <h4>
                        Brintellix demonstrates statistically significant improvements in cognitive function compared
                        with placebo, and has a significant effect vs. other therapies vs. placebo5 <span
                            class="font-size-16-blue d-inline">(as measured by
                            DSST)</span>
                    </h4>
                    <p><strong>Network meta-analysis of 12 randomised controlled trials comparing effects of various
                        antidepressant classes vs. placebo on the DSST as a measure of cognitive dysfunction in patients
                        with MDD:</strong> <sup>5</sup></p>
                    <ul class="both pt-4">
                        <li>
                            <span class="week">Brintellix was the only antidepressant class to show a statistically
                                significant improvement on DSST vs. placebo (p< 0.01)</span>
                        </li>
                        <li>
                            <span class="week">SSRIs and MAOIs had a smaller effect on DSST than placebo, while TCAs
                                negatively impacted cognitive function vs. placebo </span>
                        </li>
                        <li>
                            <span class="week">DSST was a secondary outcome in 10 out of the 12 studies </span>
                        </li>
                    </ul>
                    <div class="limitation">
                        <h4>Study limitations</h4>
                        <p>
                            Limitations of the meta-analysis include the large variability of the reported cognitive
                            outcomes in the underlying randomised controlled trials.
                        </p>
                    </div>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal7">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="font-size-20-wh">Standardised effect size on DST scores, relative to placebo</span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img12.png" alt="" /> 
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Baune BT et al. 2018.⁵</span>

                            <span class="adapted">†Antidepressants assessed (analysable number of patients in brackets):
                                SNRIs (duloxetine [n=707]), SSRIs (citalopram [n=84], escitalopram [n=54], fluoxetine
                                [n=127], sertraline [n=240]), MAOIs (phenelzine [n=28]), TCAs (desipramine [n=9],
                                nortriptyline [n=102]).
                            </span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    DSST, Digit Symbol Substitution Test; MAOI, monoamine oxidase inhibitor; MDD, Major Depressive
                    Disorder; TCA, tricyclic antidepressant; SNRI, serotonin and noradrenaline reuptake inhibitor; SSRI,
                    selective serotonin reuptake inhibitor.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- warnings section  -->
    <!-- ========================= -->
    <section class="warnings">
        <div class="container">
            <div class="warnings-warp">
                <p>
                    For further information about Brintellix, including Tolerability,
                    Special Warnings and Precautions and Contraindications, please visit
                    the About Brintellix Section
                </p>
                <a href="about_brintellix.html" class="btn-more about-btn">about brintellix</a>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- deserve section  -->
    <!-- ========================= -->
    <section class="deserve">
        <div class="container">
            <div class="deserve-wrap">
                <h3>Explore more in the sections below:</h3>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel">
        <ul class="feel-body">
            <li class="light-orange">
                <h4>
                    I want to <br />
                    FEEL
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img1.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in anhedonia and emotional blunting</p>
                </div>
                <a href="feel.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-2">
                <h4>
                    I want to
                    <br />
                    ACHIEVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img2" src="asset/image/feel-img2.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in work productivity, presenteeism and functioning</p>
                </div>
                <a href="achieve.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-3">
                <h4>
                    I want to <br />
                    MOVE FORWARD
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img3.png" alt="" />
                </figure>
                <div class="function">
                    <p>
                        Brintellix in patients with MDD together with anxiety and a
                        history of trauma
                    </p>
                </div>
                <a href="forward.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-4">
                <h4>
                    I want to <br />
                    FOCUS
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img4.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in cognition</p>
                </div>
                <a href="focus.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-5">
                <h4>
                    I want to <br />
                    MAINTAIN
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img5.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in remission and relapse</p>
                </div>
                <a href="maintain.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-6">
                <h4>
                    I want to <br />
                    LIVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img6.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix and sexual functioning</p>
                </div>

                <a href="live.html" class="btn-more btn-more-2">MORE</a>
            </li>
        </ul>
    </section>
    <!-- ========================= -->
    <!-- reference   section  -->
    <!-- ========================= -->
    <section class="reference" id="ref">
        <div class="container">
            <div class="reference-wrap">
                <div class="adverse-blk">
                    <span class="events">Adverse events should be reported.
                    </span>
                    <p>Reporting forms and information can be found at <a href="#"
                            class="yellowcard">www.mhra.gov.uk/yellowcard</a> Adverse events should
                        also be reported to Lundbeck Limited, Medical Information, on: <a class="mobile-number"
                            href="tel:01908 638972">01908 638972</a> or Email:
                        <a href="mailto:SafetyLuUnitedKingdom@lundbeck.com" class="yellowcard">
                            SafetyLuUnitedKingdom@lundbeck.com</a>

                    </p>

                </div>
                <div class="reference-cnt">
                    <span class="ref-head demi">References</span>
                    <ul class="reference-list">
                        <li>
                            <span>Lundbeck. Brintellix. Summary of Product Characteristics GB
                                and NI.</span>
                        </li>
                        <li>
                            <span>Conradi HJ et al. Psychol Med 2011;41: 1165-1174.
                            </span>
                        </li>
                        <li>
                            <span>Greer TL et al. CNS Drugs 2010;24(4): 267-284.
                            </span>
                        </li>
                        <li>
                            <span>Chokka P et al. CNS Spectr 2019;24:616–627.
                            </span>
                        </li>
                        <li>
                            <span>Baune BT et al. Int J Neuropsychopharmacol 2018;21:97–107.
                            </span>
                        </li>
                    </ul>
                    <span class="ref-head">UK-BRIN-1283 | June 2023</span>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- footer   section  -->
    <!-- ========================= -->
    <footer>
        <hr class="footer-divider" />
        <div class="container">
            <div class="row">
                <div class="footer-log d-flex">
                    <a href="#" class="footer-logo"><img src="asset/image/footer-logo.png" alt="" /></a>
                </div>
                <div class="location">
                    <p>
                        <strong class="demi">Lundbeck Limited</strong> <br />
                        Iveco House, Station Road <br />
                        Watford, Hertfordshire <br />
                        WD17 1ET <br />
                        United Kingdom
                    </p>
                    <span class="ref-head">UK-BRIN-1360 | June 2023</span>
                </div>
                <div class="contact">
                    <span class="ref-head demi">Contact us </span>
                    <a class="mail-link" href="tel:+44 1908 649 966">+44 1908 649 966</a>
                    <a href="mailto:united_kingdom@lundbeck.com" class="mail-link">united_kingdom@lundbeck.com</a>
                </div>
                <div class="footer-link-cnt">
                    <span class="ref-head demi">Links</span>
                    <ul class="footer-links">
                        <li><a href="contact.html" class="footer-link">Contact us </a></li>
                        <li><a href="terms_of_use.html" class="footer-link">Terms of Use</a></li>
                        <li>
                            <a href="#" class="footer-link">Report an Adverse Event</a>
                        </li>
                        <li>
                            <a href="privacy.html" class="footer-link">Website Privacy Policy</a>
                        </li>
                        <li><a href="cookie_policy.html" class="footer-link">Cookies settings</a></li>
                        <li>
                            <a href="asset/pdf/Brintellix Prescribing Information (April 2022) for digital use v5.pdf" target="_blank" class="footer-link">Prescribing information </a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <!----------------------- JQUERY ----------------->
    <script src="asset/js/jquery-min.js"></script>

    <!-- BOOTSTRAP JS -->
    <script src="asset/js/bootstrap.bundle.min.js"></script>
    <!----------------------- OWL CAROUSEL ----------------->
    <script src="asset/js/owl.carousel.min.js"></script>
    <!-- script js -->
    <script src="asset/js/script.js"></script>
    <!-- parallax  -->
    <script src="asset/js/parallax.js"></script>
    <!--study 1  Modal -->
    <div class="modal fade" id="study-modal6" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered  modal-dialog2">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="cao">Chokka P et al. 2019¹²</span>
                    <h3>
                        Non-randomised, interventional, open-label, flexible-dose, single-cohort study recruited
                        randomised patients receiving Brintellix at 26 sites in Canada
                    </h3>
                    <div class="rotate-sm">
                        <figure><img src="asset/image/rotate.png" alt=""></figure>
                        <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                    </div>
                    <span class="font-size-20-blue pb-2">52-week treatment period</span>
                    <figure class="vocational">
                        <img src="asset/image/vocational-img1.png" alt="" />
                    </figure>
                    <div class="analysis-cnt">
                        <p>
                            <strong> Primary efficacy analysis:</strong> to describe the correlation between change in
                            patient-reported
                            cognitive symptoms (assessed using the PDQ-D-20) and work productivity loss (assessed using
                            the WLQ) from baseline to Week 12. Baseline depression severity was controlled for in the
                            primary analysis.
                        </p>
                        <p>
                            <strong>Secondary efficacy analysis:</strong> changes in disease and symptom severity,
                            cognitive symptoms and
                            performance, work productivity, functioning, and symptoms of anxiety (QIDS-SR, CGI-S, CGl-I,
                            PDQ-D-20, DSST, WLQ productivity loss, WPAI overall impairment, SDS, WHODAS and GAD-7,
                            respectively) from baseline to Weeks 12 and 52. Treatment response rates and remission rates
                            were also calculated at Weeks 12 and 52. Safety was evaluated at Week 52 (study completion)
                            and at Week 56.
                        </p>
                        <p>
                            <strong>Tolerability:</strong> The most common treatment-emergent adverse events were nausea
                            (29.2%),
                            headache (11.9%), insomnia (9.1%), nasopharyngitis (6.8%), anxiety (6.4%), and dizziness
                            (5.9%).
                        </p>
                    </div>
                    <div class="licensed licensed2">
                        <span>*Patients received 10mg of Brintellix in the first 12 weeks of the study. From Week 12 to
                            Week 52 dosing was flexible, 10-20mg.

                        </span>
                        <span>The licensed starting dose of Brintellix for patients aged 65 or over is 5mg/day.

                        </span>
                        <p>
                            CGI-I, Clinical Global Impression - Improvement; CGI-S, Clinical Global Impression -
                            Severity; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; DSST,
                            Digit Symbol Substitution Test; GAD-7, 7-item Generalised Anxiety Disorder Scale; MDD, major
                            depressive disorder; PDQ-D-20, 20-items Perceived Deficits Questionnaire - Depression;
                            QIDS-SR, Quick Inventory of Depressive Symptomatology - Self Report; SDS, Sheehan Disability
                            Scale; WHODAS, 12-item World Health Organization Disability Assessment Schedule 2.0; WLQ,
                            Work Limitations Questionnaire; WPAI, Work Productivity and Activity Impairment.

                        </p>
                        <p><strong>References:</strong> 1. Chokka P, et al. Long-term functioning outcomes are predicted
                            by cognitive
                            symptoms in working patients with major depressive disorder treated with vortioxetine:
                            results from the AtWoRC study. CNS Spectrums. 2019 Dec;24(6):616-627. 2. Chokka P et al.
                            Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC):
                            primary analysis from a Canadian open-label study of vortioxetine in patients with major
                            depressive disorder (MDD). CNS Spectrums 2019 Jun;24(3):338-347.</p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1283 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!--study 2  Modal -->
    <div class="modal fade" id="study-modal7" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered  modal-dialog2">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="cao">Baune BT et al. 2018¹</span>
                    <h3>
                        A network meta-analysis comparing effects of various antidepressant classes vs. placebo on the
                        DSST as a measure of cognitive dysfunction in patients with major depressive disorder (MDD).
                    </h3>
                    <span class="font-size-16-br"><strong>Study objective:</strong> Assess the comparative effect of a
                        variety of antidepressants on cognitive dysfunction, as measured by DSST, in patients with MDD
                        through a systematic literature review and a network meta-analysis (NMA).</span>
                    <div class="rotate-sm">
                        <figure><img src="asset/image/rotate.png" alt=""></figure>
                        <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                    </div>
                    <!-- <span class="font-size-20-blue pt-1">Six-week double-blind treatment period</span> -->
                    <figure class="vocational">
                        <img src="asset/image/vocational-img6.png" alt="" />
                    </figure>
                    <div class="analysis-cnt">
                        <p>
                            Meta-analysis was limited to adults aged ≥18 years of age with MDD. <br>
                            DSST was a secondary outcome in 10 out of the 12 studies.
                        </p>

                    </div>
                    <div class="licensed  licensed4">
                        <span>A systematic review and network meta-analysis was conducted using a random effects model.
                            DSST, Digit Symbol Substitution Test. <br>
                            <strong>Reference: 1.</strong>  Baune BT et al. Int J Neuropsychopharmacol 2018;21:97–107.
                        </span>

                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1283 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
</body>

</html>